Login to Your Account

Biosimilar Roundup

Petition to Delay Biosimilar Game in U.S. Picks up Steam

By Mari Serebrov
Washington Editor

Friday, February 15, 2013
While other countries are building a strong lineup of biosimilars, the U.S. entry into the game could be delayed until 2022 – if Abbott Laboratories succeeds in making its case that allowing a biosimilar of a reference drug approved before March 23, 2010, would be an illegal government taking of private property.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription